BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

BACKGROUND: Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient’s survival. However, BRAF-mutated CRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Miele, Evelina, Abballe, Luana, Spinelli, Gian Paolo, Besharat, Zein Mersini, Catanzaro, Giuseppina, Chiacchiarini, Martina, Vacca, Alessandra, Po, Agnese, Capalbo, Carlo, Ferretti, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027203/
https://www.ncbi.nlm.nih.gov/pubmed/32066410
http://dx.doi.org/10.1186/s12885-020-6586-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027203/
https://www.ncbi.nlm.nih.gov/pubmed/32066410
http://dx.doi.org/10.1186/s12885-020-6586-0

Ejemplares similares